Early childhood linear growth failure in low- and middle-income countries

Jade Benjamin-Chung,[1]* Andrew Mertens,[1] John M Colford Jr,[1] Alan E Hubbard,[1] Mark J van der Laan,[1] Jeremy Coyle[1], Oleg Sofrygin,[1] Wilson Cai,[1] Anna Nguyen,[1] Nolan N Pokpongkiat,[1] Stephanie Djajadi,[1] Anmol Seth,[1] Wendy Jilek,[1] Esther O Chung,[1] Sonali Dayal,[1] Nima Hejazi,[1] Ivana Malenica,[1] Haodong Li,[1] Ryan Hafen,[2] Vishak Subramoney,[3] Jonas Häggström,[4] Thea Norman,[5] Kenneth H. Brown,[6] Parul Christian,[7] Benjamin F. Arnold,[1,8,9]* and members of the *ki* Child Growth Consortium‡

[1] Division of Epidemiology & Biostatistics, University of California, Berkeley, 2121 Berkeley Way Rm 5302 Berkeley, CA 94720-7360
[2] Hafen Consulting, LLC, West Richland WA, 99353
[3] Certara Canada, 2000 Peel St, Montreal, Quebec H3A 2W5, Canada
[4] MTEK Sciences 802-777 West Broadway, Vancouver, BC, V5Z 1J8, Canada
[5] Quantitative Sciences, Bill & Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109
[6] Department of Nutrition, University of California, Davis, 3135 Meyer Hall, Davis, CA 95616-5270
[7] Maternal, Newborn & Child Health Discovery & Tools, Bill & Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109
[8] Francis I. Proctor Foundation, University of California, San Francisco, 95 Kirkham St, San Francisco, CA 94143
[9] Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143

* Corresponding authors:

Jade Benjamin-Chung, jadebc@berkeley.edu, Division of Epidemiology & Biostatistics, University of California, Berkeley, 2121 Berkeley Way Rm 5302 Berkeley, CA 94720-7360

Benjamin F. Arnold, ben.arnold@ucsf.edu, Francis I. Proctor Foundation, University of California, San Francisco, 95 Kirkham St, San Francisco, CA 94143

Abstract

Globally 149 million children under five are estimated to be stunted (length more than 2 standard deviations below international growth standards). Stunting, a form of linear growth failure, increases risk of illness, impaired cognitive development, and mortality. Global stunting estimates rely on cross-sectional surveys, which cannot provide direct information about the timing of onset or persistence of growth failure— a key consideration for defining critical windows to deliver preventive interventions. We performed the largest pooled analysis of longitudinal studies in low- and middle-income countries to date (n=31 cohorts, 62,993 children, ages 0-24 months), allowing us to identify the typical age of linear growth failure onset and to investigate recurrent faltering in early life. The highest incidence of stunting onset occurred from birth to age 3 months. From 0 to 15 months, less than 5% of children per month reversed their stunting status, and among those who did, stunting relapse was common. Early timing and low reversal rates emphasize the importance of preventive intervention delivery within the prenatal and early postnatal phases coupled with continued delivery of postnatal interventions through the first 1000 days of life.

‡ Members of the *ki* Child Growth Consortium

1.   Souheila Abbeddou, Food Safety and Nutrition Unit, Department of Public Health and Primary
Care, Ghent University, Belgium

2.   Linda S. Adair, Department of Nutrition, University of North Carolina at Chapel Hill, USA

3.   Tahmeed Ahmed, International Centre for Diarrhoeal Disease Research, Bangladesh

4.   Asad Ali, Aga Khan University

5.   Hasmot Ali, JiVitA Project, Bangladesh, Johns Hopkins

6.   Per Ashorn, Center for Child Health Research, Tampere University and Tampere University
Hospital, Finland

7.   Rajiv Bahl, World Health Organization, Switzerland

8.   France Begín, UNICEF, USA

9.   Pascal Obong Bessong, HIV/AIDS & Global Health Research Programme, University of Venda,
South Africa

10.   Maharaj Kishan Bhan, Indian Institute of Technology, New Delhi, India

11.   Nita Bhandari, Centre for Health Research and Development, Society for Applied Studies, New
Delhi, India

12.   Santosh K. Bhargava, Senior Consultant Pediatrics, Sunder Lal Jain Hospital, Ashok Vihar, India

13.   Robert E. Black, Johns Hopkins University

14.   Ladaporn Bodhidatta, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

15.   Delia Carba, USC Office of Population Studies Foundation, Inc., University of San Carlos, Cebu,
Philippines

16.   Ines Gonzales Casanova, Rollins School of Public Health, Emory University, USA

17.   William Checkley, Johns Hopkins University, USA

19.   Jean E. Crabtree, Leeds Institute for Medical Research, St. James's University Hospital, University
of Leeds, United Kingdom

20.   Kathryn G. Dewey, Institute for Global Nutrition, Department of Nutrition, University of
California, USA

21.   Christopher P. Duggan, Center for Nutrition, Boston Children's Hospital, USA

22.   Caroline H.D. Fall, Professor of International Paediatric Epidemiology, MRC Lifecourse
Epidemiology Unit, University of Southampton, United Kingdom

23.   Abu Syed Golam Faruque, International Centre for Diarrhoeal Disease Research, Bangladesh

24.   Wafaie W. Fawzi, Department of Global Health and Population, Harvard TH Chan School of
Public Health, USA

25.   José Quirino da Silva Filho, Federal University of Ceará, Brazil

26.   Robert H. Gilman, Johns Hopkins University Bloomberg School of Public Health, USA

27.   Richard Guerrant, University of Virginia, USA

28.   Rashidul Haque, International Centre for Diarrhoeal Disease Research, Bangladesh

29.   Sonja Y. Hess, Dept of Nutrition and Institute for Global Nutrition, University of California Davis,
USA

30.   Eric R. Houpt, University of Virginia, USA

31.   Jean H. Humphrey, Johns Hopkins Bloomberg School of Public Health, USA

32.   Najeeha Talat Iqbal, Department of Pediatrics and Child Health, Aga Khan University, Pakistan

33.   Elizabeth Yakes Jimenez, Departments of Pediatrics and Internal Medicine, University of New
Mexico Health Sciences Center, USA

34.   Jacob John, Christian Medical College, Vellore, Tamil Nadu, India

35.   Sushil Matthew John, Low Cost Effective Care Unit, Christian Medical College, Vellore, Tamil
Nadu, India

36. Gagandeep Kang, Translational Health Science and Technology Institute, Faridabad, Haryana, India
37. Margaret Kosek, University of Virginia, USA
38. Michael S. Kramer, McGill University and McGill University Health Centre, Canada
39. Alain Labrique, Center of Human Nutrition, Department of International Health, Johns Hopkins Bloomberg School of Public Health, USA
40. Nanette R. Lee, USC-Office of Population Studies Foundation Inc., University of San Carlos, Cebu, Philippines
41. Aldo Ângelo Moreira Lima, Federal University of Ceará, Brazil
42. Mustafa Mahfuz, International Centre for Diarrhoeal Disease Research, Bangladesh
43. Tjale Cloupas Mahopo, Department of Nutrition, School of Health Sciences, University of Venda, South Africa
44. Kenneth Maleta, Department of Public Health, School of Public Health and Family Medicine, College of Medicine, University of Malawi, Malawi
45. Dharma S. Manandhar, Mother and Infant Research Activities, Nepal
46. Karim P. Manji, Department of Pediatrics and Child Health, Muhimbili University School of Health and Allied Sciences, Dar es Salaam, Tanzania
47. Reynaldo Martorell, Rollins School of Public Health, Emory University, USA
48. Sarmila Mazumder, Centre for Health Research and Development, Society for Applied Studies, New Delhi, India
49. Estomih Mduma, Haydom Lutheran Hospital, Haydom, Tanzania
50. Venkata Raghava Mohan, Professor, Community Medicine, Christian Medical College, Vellore Tamil Nadu, India
51. Sophie E. Moore, Department of Women and Children's Health, Kings College London, London, UK & MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, United Kingdom
52. Ishita Mostafa, International Centre for Diarrhoeal Disease Research, Bangladesh
53. Robert Ntozini, Zvitambo Institute for Maternal and Child Health Research, Zimbabwe
54. Mzwakhe Emanuel Nyathi, Department of Animal Sciences, School of Agriculture, University of Venda, South Africa
55. Maribel Paredes Olortegui, AB PRISMA, Peru
56. William A. Petri, University of Virginia, USA
57. Prasanna Samuel Premkumar, Christian Medical College, Vellore, Tamil Nadu, India
58. Andrew M. Prentice, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia
59. Najeeb Rahman, Aga Khan University, Pakistan
60. Harshpal Singh Sachdev, Senior Consultant Pediatrics and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research, B-16 Qutab Institutional Area, New Delhi, India
61. Kamran Sadiq, Aga Khan University, Pakistan
62. Rajiv Sarkar, Christian Medical College, Vellore, Tamil Nadu, India
63. Naomi M. Saville, Institute for Global Health, University College London, United Kingdom
64. Saijuddin Shaikh, Johns Hopkins and JiVitA Project, Bangladesh
65. Bhim P. Shrestha, Health Research and Development Forum, Kathmandu, Nepal
66. Sanjaya Kumar Shrestha, MD, Walter Reed/AFRIMS Research Unit, Kathmandu, Nepal, Centre for International Health, University of Bergen, Norway
67. Alberto Melo Soares, Federal University of Ceará, Brazil
68. Bakary Sonko, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia

144 69. Aryeh D. Stein, Hubert Department of Global Health, Rollins School of Public Health, Emory
145 University, USA
146 70. Erling Svensen, Haukeland University Hospital, Norway
147 71. Sana Syed, Department of Pediatrics, Division of Gastroenterology, Hepatology & Nutrition
148 University of Virginia School of Medicine, and Aga Khan University, Pakistan
149 72. Fayaz Umrani, Aga Khan University, Pakistan
150 73. Honorine D. Ward, Tufts Medical Center, Tufts University School of Medicine, USA
151 74. Keith P. West Jr., Center for Human Nutrition, Department of International Health, Johns
152 Hopkins Bloomberg School of Public Health, USA
153 75. Lee Shu Fune Wu, Center for Human Nutrition, Department of International Health, Johns
154 Hopkins Bloomberg School of Public Health, USA
155 76. Seungmi Yang, McGill University, Canada
156 77. Pablo Penataro Yori, University of Virginia, USA
157

Introduction

There have been marked reductions in child mortality in the past decade,[1] in part due to the emphasis on child survival in the Millennium Development Goals. Yet children born in low- and middle income countries (LMICs) still face enormous challenges to their ability to thrive, including poverty, poor nutrition, poor water and sanitation, poor access to health care and limited stimulation in the home environment.[2] A commonly used, readily measurable indicator of children's overall health and development is their linear growth as measured by a child's length (height or stature).[3] Extensive evidence supports its use as a surrogate for more difficult-to-measure physiological and cognitive deficits that accrue during early life.[4,5] Children in optimal environments have the same growth potential, regardless of their geographic location[6], and thus the World Health Organization (WHO) has developed international standards for child growth.[7] A child is "stunted" if his or her length is more than 2 standard deviations below the median of the growth standard for age and sex. In 2018, 149 million children under 5 years (22% globally) were stunted, with the largest burden in South Asia and Africa.[8,9] Early life stunting is associated with increased risk of mortality,[10] diarrhea, pneumonia, and measles in childhood[11,12] and impaired cognition and productivity in adulthood.[3,13,14] Global income would increase by an estimated $176.8 billion per year if linear growth failure could be eliminated.[15] The WHO 2025 Global Nutrition Targets[16] and Sustainable Development Goal 2 propose to reduce stunting prevalence from 2012 levels by 40% by 2025,[17] reflecting renewed attention to child growth as a key determinant of overall health and human capital.[18]

The age of stunting onset has direct implications for the timing and nature of preventive public health interventions. In low-resource settings, most linear growth failure occurs in the first 2 years of life, and 70% of absolute length deficits by age 5 years occur before age 2 years.[3] Beyond this age, catch up growth is rare in the absence of radical improvements to a child's nutrition, health, and environment.[19–23] Intrauterine growth restriction and preterm birth are strongly associated with the risk of stunting at 24 months of age,[24] and the first 1000 days of life is considered the critical window in which to intervene to prevent stunting.[6,25]

Granular information about age of linear growth failure onset and its persistence in early life will best inform when and how to intervene with preventive measures. Yet, most studies of the global epidemiology and burden of stunting have pooled nationally representative, cross-sectional surveys – predominantly national Demographic Health Surveys (DHS) – to estimate age-specific stunting prevalence.[23,26–28] Cross-sectional studies cannot identify the timing of linear growth failure onset because they measure prevalence, which cannot distinguish between persistent and new cases of growth failure. Few studies have reported stunting incidence,[29,30] and even fewer have estimated age-specific incidence within the first two years of life to inform the timing of intervention delivery.[31–33] We conducted an in-depth study of linear growth failure incidence in a pooled analysis of 31 longitudinal cohorts with multiple, frequent measurements in LMICs. The analysis provides new insights into the timing of onset and duration of linear growth failure, with important implications for interventions. We found that linear growth failure occurs very early in the prenatal and postnatal phase – before the age when most postnatal linear growth interventions begin (age 6 months). Our findings confirm the importance of the first 1,000 days as a critical window to intervene to prevent linear growth failure, but motivate a renewed focus on interventions delivered in the prenatal and early postnatal periods.

Pooled longitudinal analyses

Here, we report a pooled analysis of 31 longitudinal cohorts from 15 LMICs in South Asia, Sub-Saharan Africa, and Latin America followed between 1969 and 2014. Our objective was to estimate age-specific incidence and prevalence of stunting as well as linear growth velocity from 0 to 24 months. A companion article in this issue reports results for child wasting (weight-for-length Z-score < 2 standard deviations below the reference median).[34] These data were amassed as part of the Knowledge Integration (*ki*) initiative of the Bill & Melinda Gates Foundation, which aggregated observations on millions of participants from a global collection of studies on child birth, growth and development.[35] We selected longitudinal cohorts from the database that met five inclusion criteria: 1) conducted in LMICs; 2) enrolled children between birth and age 24 months and measured their length and weight repeatedly over time; 3) did not restrict enrollment to acutely ill children; 4) enrolled at least 200 children; and 5) collected anthropometry measurements at least every 3 months (Extended Data Fig 1). These inclusion criteria ensured we could rigorously evaluate the timing and onset of stunting among children who were broadly representative of general populations in LMICs. For included randomized trials, if trials found effects on growth within the intervention arms, the analysis was limited to the control arm. Thirty-one cohorts met inclusion criteria, including 62,993 children and 464,345 total measurements (Fig 1). Most cohorts were enrolled within the past 10 years (Extended Data Table 1). Cohorts were distributed throughout South Asia, Eastern, Southern, and Western Africa, and Latin America, and a single cohort from Eastern Europe (Belarus) met inclusion criteria. Among included cohorts, 18 measured children at least monthly, and 13 measured children every 3 months (quarterly). Cohort sample sizes varied from 215 to 14,074 children. Despite broad global reach, geographic distribution was not representative of entire regions or continents (Extended Data Fig 2).

We calculated length-for-age Z-scores (LAZ) using WHO 2006 growth standards.[7] We dropped 969 out of 465,314 measurements (0.2%) because LAZ was unrealistic (> 6 or < –6 Z), and we defined stunting as LAZ < –2 and severe stunting as LAZ < –3.[7] Unless otherwise indicated, estimates that pool across cohorts used random effects models fit with restricted maximum likelihood estimation.[36,37] Within each cohort the monthly mean LAZ ranged from –3.18 to +1.31, and the monthly proportion stunted ranged from 0.3% to 86.1% (Fig 1). We compared LAZ from included cohorts with those of contemporary population-based, cross-sectional DHS data for children 0-24 months of age in the same countries and regions to assess their representativeness. Cohorts had similar Z-score distributions as their target populations (Fig 2a). Mean LAZ by age was approximately 0.25-0.75 standard deviations lower in included *ki* cohorts than in DHS surveys in the same countries in South Asia and Africa, and mean LAZ by age was slightly higher in Latin American cohorts (Fig 2b). Analyses therefore include a large set of cohorts from populations with high burdens of growth failure but are not representative of entire world regions. The width of the LAZ distribution was unimodal and similar to that of the WHO child growth standard's LAZ distribution, consistent with the assertion that linear growth failure is a "whole population" condition.[27]

Age-specific patterns of mean LAZ and stunting prevalence were consistent with prior analyses of cross-sectional survey data.[26,27] Most children were born with linear growth deficits: mean LAZ at birth was -0.75 (Fig 2a). LAZ declined steadily from birth, and by 24 months mean LAZ was –1.82. South Asia had lower LAZ than other regions: mean LAZ at birth was –1.04 and the mean at 24 months was –2.01. Yet, the decline in mean LAZ was the largest in Africa, where the mean LAZ at birth was –0.56 and the mean at 24 months was –1.87. Linear growth failure was evident across percentiles of the LAZ distribution; in South Asia, the 95th percentile of children's LAZ scores dropped below 0 by age 14 months (Extended Data Fig 3). At birth, the overall prevalence of stunting (LAZ <–2) was 12%; prevalence

increased steadily to 43% at 18 months and remained stable thereafter (Fig 3a). In African cohorts,
stunting prevalence increased steadily each month from 10% at birth to 44% at 24 months. In South
Asia, 18% of children were born stunted, and stunting prevalence increased steadily to 53% at 18
months and then decreased to 48% at 24 months. At most ages, stunting prevalence and incidence were
lower in Latin America; wider confidence intervals for this region reflect greater variation between
cohorts because stunting was more common in Guatemala than in other countries (https://child-
growth.github.io/stunting/cohort.html).
261
262 **Onset of stunting in early life**
263
To measure the timing of stunting onset, we classified a child as a new incident case in three-month
age periods if their LAZ dropped below −2 for the first time in that age period. Across cohorts, 12% of
children were stunted at birth, and 17% experienced incident stunting onset between birth and 3
months (Fig 3b); children stunted between birth and 3 months accounted for 40% of all children who
experienced stunting by age 24 months (65% of children). Trends were similar for severe stunting
(https://child-growth.github.io/stunting/severe-stunting.html).
270
In an exploratory analysis, we stratified age-specific mean LAZ by age of stunting onset among
children in monthly measured cohorts and observed three distinct subgroups whose mean LAZ followed
statistically different trajectories (Fig 3c). 26% of all children were born with linear growth deficits (mean
LAZ < −1), and their mean LAZ stabilized around −2 from age 1 month onward, with differences at birth
in this group converging through likely regression to the mean. 11% of children were born with small
linear growth deficits on average (mean 0 < LAZ < −1 at birth) and reached a mean of −2 at subsequent
ages. The remaining 62% of children maintained mean LAZ > −2 at all ages, but mean LAZ declined
steadily from birth to 15 months. Overall trends in mean LAZ were consistent with our age-specific
incidence and prevalence estimates (Fig 3a-b). Children born with linear growth deficits may benefit
more from prenatal interventions, while those whose mean LAZ declined later may benefit from both
prenatal and postnatal interventions. A companion article reports characteristics that increase risk of
earlier versus later growth failure.[35]
283
284 **Stunting reversal and relapse**
285
Stunting prevalence and incidence estimates classify linear growth measures into binary categories,
which could mask the dynamics of linear growth failure onset and reversal across the continuous range
of LAZ.[5,38,39] We hypothesized that lower than average linear growth (LAZ <0) would persist among
children who experienced stunting reversal (i.e., LAZ increased from below −2 to above −2). In addition,
we hypothesized that children who experienced stunting reversal would experience stunting relapse at
later ages. To test these hypotheses, we classified a child's change in stunting status from birth to 15
months among monthly-measured cohorts (measurement frequency beyond 15 months was less
consistent) (Fig 4a). Initial onset of stunting occurred before age 6 months for a majority of children. The
proportion of children who experienced stunting reversal was less than 5% per month from ages 2 to 7
months and was lower at subsequent ages.
296
297   Among children who experienced stunting reversal, we summarized the LAZ distribution at older
298 ages. We then estimated the mean difference in LAZ measured at older ages compared to when stunting
299 was reversed. At the time of stunting reversal, the mode of the distribution of LAZ scores was close to
300 the −2 cutoff (Fig 4b). As children aged, LAZ distributions gradually shifted downwards, illustrating that
301 linear growth deficits continued to accumulate. The mean LAZ decreased by up to 0.71 SDs from 3 to 12

months after stunting reversal, and the older a child was at the time of reversal, the larger the decline in subsequent LAZ (Fig 4c). Overall, improvements in LAZ among children whose stunting status reversed were neither sustained nor large enough to erase linear growth deficits, indicating that stunting reversal did not resemble a biological recovery process for many children.

Growth velocity by age and sex

Age-specific growth velocity provides a complementary view of child growth failure only possible in longitudinal cohorts. We defined linear growth velocity as the change in length between two time points divided by the number of months between the time points (cm/month). We also estimated within-child rates of change in LAZ per month. The change in LAZ per month measures the extent to which a child's length relative to WHO standards for his or her age and sex changed over time. From 0-3 months, length velocity was in between the 15th and 25th percentile of the WHO standard for girls and was close to the 15th percentile for boys; velocity for both sexes then improved relative to WHO standards as children aged (Fig 5a). Larger deficits at the youngest ages were consistent with highest incidence of stunting from birth to age 3 months (Fig 3b). LAZ velocity was similar for male and female children (Fig 5b). Patterns were similar across geographic regions (Extended Data Fig 4a, 4b).

The accumulation of growth velocity deficits was reflected in lower mean LAZ for boys than girls across all ages (Fig 5c). Overall patterns were similar across geographic regions (Extended Data Fig 4c). Worse growth among boys is consistent with higher infant mortality rates among boys found around the world, suggesting that males may be more vulnerable than females in early life,[40–46] or that evolutionary selection favors females in resource-poor environments.[47]

Discussion

Estimates of the global burden of stunting and timing of linear growth failure have relied largely on cross-sectional surveys that have indicated the need for interventions targeted to children younger than 24 months.[6,25] This large-scale, longitudinal analysis of 31 prospective cohorts from LMICs allowed us to provide new insights into the timing, persistence, and recurrence of linear growth failure within the first 2 years of life. Prevalence estimates matched general patterns reported in cross-sectional studies, gradually increasing with age.[23,26–28] Yet, incidence estimates from longitudinal analyses revealed a starkly different age-specific pattern and showed that stunting incidence was highest from birth to 3 months and declined thereafter (Fig 3a-b). The vast majority of children who experienced stunting reversal (i.e., crossed above the <–2 LAZ cut-off) continued to experience linear growth deficits, and over 20% were stunted again at later measurements (Fig 4).

Pre-pregnancy and prenatal risk factors for postnatal linear growth failure include young maternal age,[48] maternal infection,[49] and maternal undernutrition, including low pre-pregnancy body mass index, short stature, and inadequate gestational weight gain.[50] Rigorous evaluations of interventions to address these predictors have been limited to date. Interventions to improve maternal nutrition[51] and reduce adolescent pregnancies in LMICs by delaying the age of marriage and first pregnancy[52] may reduce the risk of linear growth failure. In addition, interventions to reduce prenatal infections associated with growth failure, such as intermittent preventive treatment for malaria, may also increase fetal linear growth in regions where such infections co-occur with linear growth failure.[53]

In the early postnatal phase (age 0-6 months), when growth velocity and stunting incidence were highest, the World Health Organization recommends exclusive breastfeeding to prevent infant infection

and to support child growth.[54] Exclusive breastfeeding significantly reduces the risk of mortality and
morbidity, but exclusive breastfeeding promotion has not been found to reduce the risk of infant
stunting.[11,55–58] The extent to which exclusive breastfeeding impacts linear growth may depend on
maternal breast milk composition and microbiota, both of which may be impacted by maternal
undernutrition.[59–61] In the complementary feeding phase (age 6-24 months), interventions to reduce
growth failure include energy, protein, and micronutrient supplementation of children; deworming;
water and sanitation improvements; vaccination; and maternal education. However, meta-analyses
evaluating the effectiveness of interventions during the complementary feeding phase on stunting
prevalence and mean LAZ have reported modest impacts of lipid-based nutrient supplements,[62] modest
or no impact of micronutrient supplementation,[63] and no impact of water and sanitation improvements,
deworming, or maternal education.[63] The dearth of postnatal interventions that can effectively improve
child linear growth motivates renewed efforts to identify alternative, possibly multisectoral
interventions, and in parallel improve intervention targeting and implementation.[64,65]
363
There were several limitations to the analyses. First, length estimates may be subject to
measurement error; stunting reversal and relapse analyses that rely on thresholds are more sensitive to
such errors. However, detailed assessments of measurement quality indicated that measurement
quality was high across cohorts (https://child-growth.github.io/stunting/QA.html). Second, estimates of
LAZ at birth using the WHO Child Growth Standards overestimate stunting among children who are born
preterm.[66] Accurate estimates of gestational age were not available in included cohorts; seven cohorts
measured gestational age by recall of last menstrual period or newborn examination, and one cohort
measured gestational age by ultrasound. In a sensitivity analysis adjusting for gestational age pooling
across cohorts that measured it, stunting prevalence at birth was 1% lower (Extended Data Fig 5). Third,
included cohorts were not inclusive of all countries in the regions presented here, and linear growth
failure was more common in included African and South Asian cohorts than in corresponding
contemporary representative surveys. However, the consistency between linear growth patterns in this
and nationally representative surveys (Fig 2) suggests that overall our results have good external
validity. Finally, the included cohorts measured child length every 1-3 months, and the exact ages of
measurement varied, so the number of children and cohorts contributing to estimates differs between
analysis strata. However, when we repeated analyses in cohorts with monthly measurements from birth
to 24 months (n=18 cohorts in 10 countries, 10,830 children), results were similar (https://child-
growth.github.io/stunting/monthly.html).
382
Conclusion
The WHO Global Nutrition Targets and Sustainable Development Goals set ambitious targets to
improve child linear growth by 2025. Our findings of early linear growth failure onset and infrequent
reversal for a majority of children who faltered support interventions delivered from conception to the
early postnatal phase along with continued delivery of postnatal interventions to prevent linear growth
failure among children in LMICs.
389

References

1. UNICEF. Levels and Trends in Child Mortality Report 2018. *UNICEF*
   https://www.unicef.org/publications/index_103264.html (2018).

2. Bhutta, Z. A. & Black, R. E. Current and Future Challenges for Children Across the World. *JAMA*
   (2019) doi:10.1001/jama.2019.1840.

3. de Onis, M. & Branca, F. Childhood stunting: a global perspective. *Matern. Child. Nutr.* **12**, 12–26
   (2016).

4. Grantham-McGregor, S. *et al.* Developmental potential in the first 5 years for children in developing
   countries. *Lancet* **369**, 60–70 (2007).

5. Leroy, J. L. & Frongillo, E. A. Perspective: What Does Stunting Really Mean? A Critical Review of the
   Evidence. *Adv. Nutr.* doi:10.1093/advances/nmy101.

6. Martorell, R. Improved nutrition in the first 1000 days and adult human capital and health. *Am. J.
   Hum. Biol.* **29**, e22952 (2017).

7. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-
   age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods
   and development. *Geneva World Health Organ.* 312 pages (2006).

8. *WHO | Joint child malnutrition estimates - Levels and trends (2019 edition)*.
   http://www.who.int/nutgrowthdb/estimates2018/en/ (2019).

9. Kinyoki, D. K. *et al.* Mapping child growth failure across low- and middle-income countries. *Nature*
   577, 231–234 (2020).

10. McDonald, C. M. *et al.* The effect of multiple anthropometric deficits on child mortality: meta-
    analysis of individual data in 10 prospective studies from developing countries. *Am. J. Clin. Nutr.* **97**,
    896–901 (2013).

11. Black, R. E. *et al.* Maternal and child undernutrition and overweight in low-income and middle-
    income countries. *The Lancet* **382**, 427–451 (2013).

12. Olofin, I. *et al.* Associations of Suboptimal Growth with All-Cause and Cause-Specific Mortality in

Children under Five Years: A Pooled Analysis of Ten Prospective Studies. *PLoS ONE* **8**, (2013).

13. Prendergast, A. J. & Humphrey, J. H. The stunting syndrome in developing countries. *Paediatr. Int.*

Child Health **34**, 250–265 (2014).

14. Adair, L. S. *et al.* Associations of linear growth and relative weight gain during early life with adult

health and human capital in countries of low and middle income: findings from five birth cohort

studies. *Lancet* **382**, 525–534 (2013).

15. Fink, G. *et al.* Schooling and wage income losses due to early-childhood growth faltering in

developing countries: national, regional, and global estimates. *Am. J. Clin. Nutr.* **104**, 104–112

(2016).

16. World Health Organization. Global Targets 2025. *WHO* http://www.who.int/nutrition/global-target-

2025/en/.

17. United Nations. Goal 2. Sustainable Development Knowledge Platform.

https://sustainabledevelopment.un.org/sdg2.

18. Victora, C. G. *et al.* Maternal and child undernutrition: consequences for adult health and human

capital. *Lancet* **371**, 340–357 (2008).

19. Dewey, K. G. & Begum, K. Long-term consequences of stunting in early life. *Matern. Child. Nutr.* **7**,

5–18 (2011).

20. Golden, M. H. Is complete catch-up possible for stunted malnourished children? *Eur. J. Clin. Nutr.* **48**

Suppl 1, S58-70; discussion S71 (1994).

21. Boersma, B. & Wit, J. M. Catch-up Growth. *Endocr. Rev.* **18**, 646–661 (1997).

22. Prentice, A. M. *et al.* Critical windows for nutritional interventions against stunting123. *Am. J. Clin.*

Nutr. **97**, 911–918 (2013).

23. Leroy, J. L., Ruel, M., Habicht, J.-P. & Frongillo, E. A. Using height-for-age differences (HAD) instead

of height-for-age z-scores (HAZ) for the meaningful measurement of population-level catch-up in

linear growth in children less than 5 years of age. *BMC Pediatr.* **15**, 145 (2015).

24. Christian, P. *et al.* Risk of childhood undernutrition related to small-for-gestational age and preterm

birth in low- and middle-income countries. *Int J Epidemiol* **42**, 1340–1355 (2013).

25. Dewey, K. G. Reducing stunting by improving maternal, infant and young child nutrition in regions

such as South Asia: evidence, challenges and opportunities. *Matern. Child. Nutr.* **12**, 27–38 (2016).

26. Victora, C. G., Onis, M. de, Hallal, P. C., Blössner, M. & Shrimpton, R. Worldwide Timing of Growth

Faltering: Revisiting Implications for Interventions. *Pediatrics* **125**, e473–e480 (2010).

27. Roth, D. E. *et al.* Early childhood linear growth faltering in low-income and middle-income countries

as a whole-population condition: analysis of 179 Demographic and Health Surveys from 64 countries

(1993–2015). *Lancet Glob. Health* **5**, e1249–e1257 (2017).

28. Leroy, J. L., Ruel, M., Habicht, J.-P. & Frongillo, E. A. Linear growth deficit continues to accumulate

beyond the first 1000 days in low- and middle-income countries: global evidence from 51 national

surveys. *J. Nutr.* **144**, 1460–1466 (2014).

29. Kumar, R., Deshmukh, P. R. & Garg, B. S. Incidence and Correlates of "Growth Faltering" Among 0–6

y Children: A Panel Study from Rural Wardha. *Indian J. Pediatr.* **79**, 333–341 (2012).

30. Lundeen, E. A. *et al.* Growth faltering and recovery in children aged 1–8 years in four low- and

middle-income countries: Young Lives. *Public Health Nutr.* **17**, 2131–2137 (2014).

31. Mangani, C. *et al.* Effect of complementary feeding with lipid-based nutrient supplements and corn–

soy blend on the incidence of stunting and linear growth among 6- to 18-month-old infants and

children in rural Malawi. *Matern. Child. Nutr.* **11**, 132–143 (2015).

32. Maleta, K., Virtanen, S. M., Espo, M., Kulmala, T. & Ashorn, P. Childhood malnutrition and its

predictors in rural Malawi. *Paediatr. Perinat. Epidemiol.* **17**, 384–390 (2003).

33. Mongkolchati, A., Thinkhamrop, B., Mo-Suwan, L., Chittchang, U. & Choprapawon, C. Prevalence

and incidence of child stunting from birth to two years of life in Thai children: based on the

Prospective Cohort Study of Thai Children (PCTC). *J. Med. Assoc. Thail. Chotmaihet Thangphaet* **93**,

1368–1378 (2010).

34. Mertens, A. *et al.* (submitted). Child wasting and concurrent stunting in low- and middle-income

countries. (2020).

35. Peppard, T. *et al.* (submitted). Combined longitudinal growth cohorts from infants born in South

Asia, Sub-Saharan Africa and Latin America. (2020).

36. Viechtbauer, W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects

Model. *J. Educ. Behav. Stat.* **30**, 261–293 (2005).

37. Raudenbush, S. W. Analyzing Effect Sizes: Random-Effects Models. in *The Handbook of Research*

Synthesis and Meta-Analysis 295–315 (Russell Sage Foundation, 2009).

38. Frongillo, E. A., Leroy, J. L. & Lapping, K. Appropriate Use of Linear Growth Measures to Assess

Impact of Interventions on Child Development and Catch-Up Growth. *Adv. Nutr.*

doi:10.1093/advances/nmy093.

39. Perumal, N., Bassani, D. G. & Roth, D. E. Use and Misuse of Stunting as a Measure of Child Health. *J.*

Nutr. **148**, 311–315 (2018).

40. Leach, A. *et al.* Neonatal mortality in a rural area of The Gambia. *Ann. Trop. Paediatr.* **19**, 33–43

(1999).

41. Koenig, M. A. & D'Souza, S. Sex differences in childhood mortality in rural Bangladesh. *Soc. Sci. Med.*

22, 15–22 (1986).

42. Wells, J. C. K. Natural Selection and Sex Differences in Morbidity and Mortality in Early Life. *J. Theor.*

Biol. **202**, 65–76 (2000).

43. Ingemarsson, I. Gender aspects of preterm birth. *BJOG Int. J. Obstet. Gynaecol.* **110**, 34–38 (2003).

44. Sawyer, C. C. Child Mortality Estimation: Estimating Sex Differences in Childhood Mortality since the

1970s. *PLOS Med.* **9**, e1001287 (2012).

45. Lawn, J., Cousens, S. & Zupan, J. 4 million neonatal deaths: When? Where? Why? *The Lancet* **365**,

891–900 (2005).

46. Hesketh, T. & Xing, Z. W. Abnormal sex ratios in human populations: Causes and consequences.

Proc. Natl. Acad. Sci. U. S. A. **103**, 13271–13275 (2006).

47. Trivers, R. L. & Willard, D. E. Natural Selection of Parental Ability to Vary the Sex Ratio of Offspring.

Science **179**, 90–92 (1973).

48. Fall, C. H. D. *et al.* Association between maternal age at childbirth and child and adult outcomes in

the offspring: a prospective study in five low-income and middle-income countries (COHORTS

collaboration). *Lancet Glob. Health* **3**, e366–e377 (2015).

49. Ashorn, P. *et al.* Co-causation of reduced newborn size by maternal undernutrition, infections, and

inflammation. *Matern. Child. Nutr.* **14**, e12585 (2018).

50. Black, R. E. *et al.* Maternal and child undernutrition: global and regional exposures and health

consequences. *Lancet* **371**, 243–260 (2008).

51. Das, J. K. *et al.* Lipid-based nutrient supplements for maternal, birth, and infant developmental

outcomes. *Cochrane Database Syst. Rev.* **8**, CD012610 (2018).

52. Svanemyr, J., Chandra-Mouli, V., Raj, A., Travers, E. & Sundaram, L. Research priorities on ending

child marriage and supporting married girls. *Reprod. Health* **12**, 80 (2015).

53. Luntamo, M., Kulmala, T., Cheung, Y. B., Maleta, K. & Ashorn, P. The effect of antenatal monthly

sulphadoxine–pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering

in Malawi: a randomised controlled trial. *Trop. Med. Int. Health* **18**, 386–397 (2013).

54. WHO & UNICEF. *Capture the moment - Early initiation of breastfeeding: the best start for every*

newborn. (2018).

55. Victora, C. G. *et al.* Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong

effect. *The Lancet* **387**, 475–490 (2016).

56. Bhutta, Z. A. *et al.* What works? Interventions for maternal and child undernutrition and survival.

The Lancet **371**, 417–440 (2008).

57. Giugliani, E. R. J., Horta, B. L., Mola, C. L. de, Lisboa, B. O. & Victora, C. G. Effect of breastfeeding

promotion interventions on child growth: a systematic review and meta-analysis. *Acta Paediatr.*

104, 20–29 (2015).

58. Eriksen, K. G. *et al.* Following the World Health Organization's Recommendation of Exclusive

Breastfeeding to 6 Months of Age Does Not Impact the Growth of Rural Gambian Infants. *J. Nutr.*

147, 248–255 (2017).

59. Emmett, P. M. & Rogers, I. S. Properties of human milk and their relationship with maternal

nutrition. *Early Hum. Dev.* **49**, S7–S28 (1997).

60. Bravi, F. *et al.* Impact of maternal nutrition on breast-milk composition: a systematic review. *Am. J.*

Clin. Nutr. **104**, 646–662 (2016).

61. Robertson, R. C., Manges, A. R., Finlay, B. B. & Prendergast, A. J. The Human Microbiome and Child

Growth – First 1000 Days and Beyond. *Trends Microbiol.* **27**, 131–147 (2019).

62. Das, J. K. *et al.* Preventive lipid-based nutrient supplements given with complementary foods to

infants and young children 6 to 23 months of age for health, nutrition, and developmental

outcomes. *Cochrane Database Syst. Rev.* **5**, CD012611 (2019).

63. Park, J. J. H. *et al.* Association of Early Interventions With Birth Outcomes and Child Linear Growth in

Low-Income and Middle-Income Countries: Bayesian Network Meta-analyses of Randomized Clinical

Trials. *JAMA Netw. Open* **2**, e197871–e197871 (2019).

64. Casanovas, M. del C. *et al.* Multi-sectoral interventions for healthy growth - Carmen Casanovas -

2013 - Maternal & Child Nutrition - Wiley Online Library. *Matern. Child. Nutr.* **9**, 46–57 (2013).

65. Ruel, M., Alderman, H. & Maternal and Child Nutrition Study Group. Nutrition-sensitive

interventions and programmes: how can they help to accelerate progress in improving maternal and

child nutrition? *Lancet* **382**, 536–51 (2013).

66. Perumal, N. *et al.* Effect of correcting for gestational age at birth on population prevalence of early

childhood undernutrition. *Emerg. Themes Epidemiol.* **15**, 3 (2018).

539
540

Figure 1 | Summaries of included *ki* cohorts. (a) Number of observations (1000s) by age in months. **(b)**
Mean length-for-age Z-scores by age in months for each cohort. Cohorts are sorted by geographic region
and mean length-for-age Z-score. **(c)** Number of observations contributed by each cohort. **(d)** Overall
stunting prevalence in each cohort, defined as proportion of measurements with length-for-age z-score
< −2.

548
Figure 2 | Length-for-age Z-scores by age and region. (**a**) Kernel density distributions of length-for-age
z-scores (LAZ) in Demographic and Health Surveys (DHS) in countries that overlap with *ki* cohorts
stratified by geographic region. DHS estimates use the most recent survey from all countries in each
region. Open circles indicate median LAZ in *ki* cohorts; closed circles indicate median LAZ in DHS cohorts.
(**b**) Mean LAZ by age for DHS studies and *ki* longitudinal cohorts with at least quarterly measurement
estimated with cubic splines. Shaded bands are approximate 95% simultaneous confidence intervals.
555

Figure 3 | Prevalence and incidence of stunting by age and region. (**a**) Age-specific stunting prevalence
and (**b**) Age-specific stunting incidence (cumulative and new cases) overall (N=21-30 studies; N=13,349-
52,389 children) and stratified by region (Africa: N=4-7 studies, N=4,396-15,666 children; Latin America:
N=3-5 studies, N=705-1,460 children; South Asia 12-18 studies, N=6,592-28,785 children). "0-3" includes
age 2 days up to 3 months. Panels (a) and (b) include cohorts with at least quarterly measurements;
vertical bars indicate 95% confidence intervals. (**c**) Mean length-for-age Z-score (LAZ) stratified by age of

incident stunting from birth to age 15 months (N=14 cohorts that measured children at least monthly
between birth and age 15 months, N=7,198 children). "Never" includes children who did not become
stunted by age 15 months. Shaded ribbons indicate 95% confidence intervals. Pooled results were
derived from random effects models with restricted maximum likelihood estimation.
571
572

a

b

Figure 4| Relationship between LAZ and stunting status. (**a**) Percentage of children stunted and not
stunted by age (N=18 cohorts with at least monthly measurements, N=10,669 children). (**b**) Distribution
of LAZ at subsequent measurements after stunting reversal. (**c**) Mean difference in LAZ following
stunting reversal at each subsequent age of measurement compared to the age of reversal using
random effects models fit with restricted maximum likelihood estimation. (b) and (c) include data from
18 cohorts in 10 countries with at least monthly measurement (N = 10,677 children). All panels contain
data up to age 15 months because in most cohorts; measurements were less frequent above 15 months.

587
588
Figure 5| Linear growth velocity by age and sex. (**a**) Within-child difference in length in centimeters per
month stratified by age among male (green line) and female (orange line) children; 15th percentile of the
WHO Growth Velocity Standards (dotted black lines); 25th percentile (dashed black line); and the 50th
percentile (solid black line). Differences were statistically significant between sexes at ages 0-3, 3-6, 15-
18, and 18-21 months. (**b**) Within-child difference in length-for-age Z-score per month by age and sex.
Differences were statistically significant between sexes at ages 0-3, , 9-12, 12-15, 18-21, and 21-24
months. (**c**) Mean length-for-age Z-score by age and sex; all differences were statistically significant. All
panels include 29 *ki* cohorts in 13 countries that measured children at least quarterly (n = 50,022
children) pooled using random effects models fit with restricted maximum likelihood estimation.
Vertical bars indicate 95% confidence intervals.

Materials and Methods

Study designs and inclusion criteria
We included all longitudinal observational studies and randomized trials available through the *ki* project on April 2018 that met 5 inclusion criteria: 1) conducted in low- or middle-income countries; 2) enrolled children between birth and age 24 months and measured their length and weight repeatedly over time; 3) did not restrict enrollment to acutely ill children; 4) enrolled at least 200 children; 5) collected anthropometry measurements at least every 3 months (Extended Data Figure 1). Thirty-one longitudinal cohorts in 15 countries followed between 1969 and 2014 met inclusion criteria. There was no evidence of secular trends in LAZ (https://child-growth.github.io/stunting/secular-trends.html). We calculated cohort measurement frequency as the median days between measurements. If randomized trials found effects on growth within the intervention arms, the analyses were limited to the control arm. We included all measurements under 24 months of age, assuming months were 30.4167 days. We excluded extreme measurements of LAZ > 6 or < −6 following WHO growth standard recommendations.[1] In many studies, investigators measured length shortly after birth because deliveries were at home, but the majority of measurements were within the first 7 days of life (https://child-growth.github.io/stunting/age-meas.html); for this reason, we grouped measurements in the first 7 days as birth measurements. Gestational age was measured in only eight cohorts (7 cohorts measured it by recall of last menstrual period or newborn examination; 1 measured it by ultrasound); thus, we did not attempt to exclude preterm infants from the analyses.

Quality assurance
The *ki* data team assessed the quality of individual cohort datasets by checking the range of each variable for outliers and values that are not consistent with expectation. Z-scores were calculated using the median of replicate measurements and the 2006 WHO Child Growth Standards.[1] In a small number of cases a child had two anthropometry records at the same age, in which case we used the mean of the records. Analysts reviewed bivariate scatter plots to check for expected correlations (e.g., length by height, length/height/weight by age, length/height/weight by corresponding Z-score). Once the individual cohort data was mapped to a single harmonized dataset, analysts conducted an internal peer review of published articles for completeness and accuracy. Analysts contacted contributing investigators to seek clarification about potentially erroneous values in the data and revised the data as needed.

Outcome definitions
We used the following summary measures in the analysis:

Prevalent stunting was defined as the proportion of measurements within a specific stratum (e.g., age) below the 2006 WHO standard −2 LAZ, and analogously below −3 LAZ for severe stunting. For each age, we included children with LAZ measurements within one month before and after that age in the point prevalence estimate to account for variation in the exact age of child measurement. For example, point prevalence at 6 months included children aged 5-7 months.

Incident stunting episodes were defined as a change in LAZ from above −2 Z in the prior measurement to below −2 Z in the current measurement. Similarly, we defined severe stunting episodes using the −3 Z cutoff. Children were considered at risk of stunting at birth, so children born stunted were considered to have an incident episode of stunting at birth. Children were also assumed to be at risk of stunting at the first measurement in non-birth cohorts and trials. Children whose first measurement occurred after

birth were assumed to have experienced stunting onset at the age halfway between birth and the first
measurement. The vast majority of children were less than 5 days of age at their first measurement life
(https://child-growth.github.io/stunting/age-meas.html).

Incidence proportion We calculated the incidence proportion of stunting during a defined age range
(e.g. 3-6 months) as the proportion of children at risk of becoming stunted who became stunted during
the age range (the onset of new episodes).

Changes in stunting status were classified using the following categories: "Never stunted": children with
LAZ ≥−2 at previous ages and the current age. "No longer stunted": children who previously reversed
their stunting status with LAZ ≥−2 at the current age. "Stunting reversal": children with LAZ <−2 at the
previous age and LAZ ≥ −2 at the current age. "Newly stunted": children whose LAZ was previously
always ≥−2 and with LAZ <−2 at the current age. "Stunting relapse": children who were previously
stunted with LAZ ≥−2 at the previous age and LAZ <−2 at the current age. "Still stunted": children whose
LAZ was <−2 at the previous and current age.

Growth velocity was calculated as the change in length in centimeters between two time points divided
by the number of months between the time points. We compared the change in length in centimeters
per month measures to the WHO Child Growth Standards for linear growth velocity.[2] We also estimated
within-child rates of change in LAZ per month.

Measurement frequency
670 Analyses of prevalence, incidence, and growth velocity (Figs 2, 3, 5) included cohorts with at least
671 quarterly measurements in order to include as many cohorts as possible. Analyses of fluctuations in
672 stunting status (Fig 4) were restricted to cohorts with at least monthly measurements to allow
673 evaluation of changes in stunting status with higher resolution.

Subgroups of interest
676 We stratified the above outcomes within the following subgroups: child age, grouped into one- or three-
677 month intervals, (depending on the analysis); the region of the world (Asia, sub-Saharan Africa, Latin
678 America); child sex, and the combinations of those categories.

Statistical analysis
All analyses were conducted in R version 3.4.2.[3]

Estimation of mean LAZ by age in Demographic and Health Surveys and *ki* cohorts

We downloaded standard DHS individual recode files for each country from the DHS program
website (https://dhsprogram.com/). We used the most recent standard DHS datasets for the individual
women's, household, and height and weight datasets from each country. We obtained variables for
country code, sample weight, cluster number, primary sampling unit, and design stratification from the
women's individual survey recode files. From the height and weight dataset, we used standard recode
variables corresponding to the 2006 WHO growth standards for height-for-age.

After excluding missing observations, restricting to measurements of children 0-24 months of age,
and restricting to z-scores within WHO-defined plausible values, surveys collected from 2006 to 2018 in
51 countries were included (Extended Data Table 2). Surveys from Afghanistan, Bolivia, Brazil, Central

African Republic, Colombia, Indonesia, Nicaragua, Philippines, Paraguay, and Vietnam did not meet
these inclusion criteria and were excluded from the analysis.
697
698   We classified countries into regions (South Asia, Latin America, and Africa) using the World Health
699 Organization regional designations with the exception of the classification for Pakistan, which we
700 included in South Asia to be consistent with prior linear growth studies using DHS.[4] One included cohort
701 was from Belarus, and we chose to exclude it from region-stratified analyses as it was the only European
702 study.
703
We estimated age-stratified mean from ages 0 to 24 months within each DHS survey, accounting for
the complex survey design and sampling weights. We then pooled estimates of mean LAZ for each age in
months across countries using a fixed effects estimator (details below). We computed two sets of
pooled results: 1) DHS measuring children 0-24 months in countries that overlapped with *ki* study
countries and 2) all DHS countries measuring children 0-24 months in each geographic region (as in Fig
2) and (https://child-growth.github.io/stunting/DHS.html). We compared DHS estimates with mean LAZ
by age in the ki study cohorts, which we estimated using penalized cubic-splines with bandwidth chosen
using generalized cross-validation.[5] We used splines to estimate age-dependent mean LAZ in the *ki* study
cohorts to smooth any age-dependent variation in the mean caused by less frequently measured
cohorts.
714
715 <u>Fixed and random effects models</u>
716
Several analyses pooled results across study cohorts. The primary method of pooling was using random
effects models. This modeling approach assumes that studies are randomly drawn from a hypothetical
population of longitudinal studies that could have been conducted on children's linear growth in the
past or future. We also fit fixed effects models as a sensitivity analysis (https://child-
growth.github.io/stunting/fixed-effects.html); inferences about estimates from fixed effects models are
restricted to only the included studies.[6]
723
724   Random effects models assume that the true population outcomes θ are normally distributed with
725 mean μ and variance τ^2 (i.e., that $\theta \sim \mathrm{N}(\mu, \tau^2)$). To estimate outcomes in this study, the random effects
726 model is defined as follows for each study in the set of $i = 1, \ldots, k$ studies:
727
728     $y_i = \mu + u_i + e_i$ (1)
729
where y_i is the observed outcome in study i, u_i is the random effect for study i, and e_i is the estimated
outcome for study i, and e_i is the sampling error within study i. The model assumes that $u_i \sim \mathrm{N}(0, \tau^2)$ and
$e_i \sim \mathrm{N}(0, v_i)$, where v_i is the study-specific sampling variance. We fit random effects models using the
restricted maximum likelihood estimator.[7,8] If a model failed to converge, models were fit using a
maximum likelihood estimator instead. The estimate of μ is the estimated mean outcome in the
hypothetical population of studies (i.e., the estimated outcome pooling across study cohorts).
736
737   We also fit inverse variance weighted fixed effects models defined as follows:
738

$$\bar{\theta}_w = \sum_{i=1}^{k} w_i \theta_i \bigg/ \sum_{i=1}^{k} w_i$$

739   (2)
740

where $\overline{\theta}_w$ is the weighted mean outcome in the set of *k* included studies, and w_i is a study-specific
weight, defined as the inverse of the study-specific sampling variance v_i. $\overline{\theta}_w$ is the estimated mean
outcome in the specific studies included in this analysis.

For both types of outcomes, we pooled binary outcomes on the logit scale and then back-
transformed estimates after pooling to constrain confidence intervals between 0 and 1. For cohort-
stratified analyses, which did not pool across studies, we estimated 95% confidence intervals using the
normal approximation (https://child-growth.github.io/stunting/cohort.html).

For the estimates of changes in stunting status, to ensure that percentages summed to 100%, results
in Fig 4a were not pooled using random effects. Results were similar when pooling with random effects
(https://child-growth.github.io/stunting/fixed-effects.html#changes-in-stunting-status-by-age).

<u>Estimation of prevalence and incidence</u>
We estimated prevalence and incidence as defined above in 3-month age intervals within specific
cohorts and pooled within region and across all studies (Fig 3). Pooled analyses used random effects
models for the primary analysis and fixed effects models for sensitivity analyses as described above.

<u>Estimation of changes in stunting status</u>
To assess fluctuations in stunting status over time, we conducted an analysis among cohorts with at
least monthly measurements from birth through age 15 months to provide sufficient granularity to
capture changes in stunting status. Because only 12 cohorts in 10 countries met these criteria, we
performed only pooled analyses (i.e., we did not stratify by region or study cohort) to ensure the sample
size was sufficient. We estimated the proportion of children in each stunting category defined above
under "Changes in stunting status" at each month from birth to 15 months. To ensure that percentages
summed to 100%, we present results that were not pooled using random effects. Analyses using random
effects produced similar results (https://child-growth.github.io/stunting/fixed-effects.html#changes-in-
stunting-status-by-age).

To examine the distribution of LAZ among children with stunting reversal, we created subgroups of
children who experienced stunting reversal at ages 3, 6, 9, and 12 months and then summarized the
distribution of the children's LAZ at ages 6, 9, 12, and 15 months. Within each age interval, we estimated
the mean difference in LAZ at older ages compared to the age of stunting reversal and estimated 95%
confidence intervals for the mean difference. Pooled analyses used random effects models for the
primary analysis and fixed effects models for sensitivity analyses as described above.

<u>Linear growth velocity</u>
We estimated linear growth velocity within 3-month age intervals stratified by sex, pooling across
study cohorts (Fig 5) as well as stratified by geographic region (Extended Data Fig 4) and study cohort
(https://child-growth.github.io/stunting/cohort.html). Analyses included cohorts that measured children
at least quarterly. We included measurements within a two-week window around each age in months to
account for variation in the age of each length measurement. Pooled analyses used random effects
models for the primary analysis and fixed effects models for sensitivity analyses as described above
(https://child-growth.github.io/stunting/fixed-effects.html).

Sensitivity Analyses
We conducted three sensitivity analyses; results are available at (https://child-
growth.github.io/stunting). First, to assess whether inclusion of PROBIT, the single European cohort,

influenced our overall pooled inference, we repeated analyses excluding the PROBIT cohort. Results
were very similar with and without the PROBIT cohort. Second to explore the influence of differing
numbers of cohorts contributing data at different ages, we conducted a sensitivity analysis in which we
subset data to cohorts that measured anthropometry monthly from birth to 24 months (n=8 cohorts in 8
countries, 8,457 children. Third, we compared estimates pooled using random effects models presented
in the main text with estimates pooled using fixed effects inverse variance weighted models. The
random effects approach was more conservative in the presence of study heterogeneity.
796
797 **Data and code availability:** The data that support the findings of this study are available from the Bill
798 and Melinda Gates Foundation Knowledge Integration project upon reasonable request. Replication
799 scripts for this analysis are available here: https://github.com/child-growth/ki-longitudinal-growth.
800

Methods References

1. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-

age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods

and development. *Geneva World Health Organ.* 312 pages (2006).

2. WHO. *WHO Child Growth Standards: Growth Velocity Based on Weight, Length and Head*

Circumference: Methods and Development. (2009).

3. R Core Team. *R: A language and environment for statistical   computing*. https://www.R-project.org/

(2019).

4. Victora, C. G., de Onis, M., Hallal, P. C., Blössner, M. & Shrimpton, R. Worldwide timing of growth

faltering: revisiting implications for interventions. *Pediatrics* **125**, e473-480 (2010).

5. Wood, S. N., Pya, N. & Säfken, B. Smoothing Parameter and Model Selection for General Smooth

Models. *J. Am. Stat. Assoc.* **111**, 1548–1563 (2016).

6. Hedges, L. V. & Vevea, J. L. Fixed- and random-effects models in meta-analysis. *Psychol. Methods* **3**,

486–504 (1998).

7. Viechtbauer, W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects

Model. *J. Educ. Behav. Stat.* **30**, 261–293 (2005).

8. Raudenbush, S. W. Analyzing Effect Sizes: Random-Effects Models. in *The Handbook of Research*

Synthesis and Meta-Analysis 295–315 (Russell Sage Foundation, 2009).

Acknowledgments

This research was financially supported by a global development grant (OPP1165144) from the Bill & Melinda Gates Foundation to the University of California, Berkeley, CA, USA. We would also like to thank the following collaborators on the included cohorts and trials for their contributions to study planning, data collection, and analysis: Muhammad Sharif, Sajjad Kerio, Ms. Urosa, Ms. Alveen, Shahneel Hussain, Vikas Paudel (Mother and Infant Research Activities), Anthony Costello (University College London), Benjamin Torun, Lindsey M Locks, Christine M McDonald, Roland Kupka, Ronald J Bosch, Rodrick Kisenge, Said Aboud, Molin Wang, Azaduzzaman, Abu Ahmed Shamim, Rezaul Haque, Rolf Klemm, Sucheta Mehra, Maithilee Mitra, Kerry Schulze, Sunita Taneja, Brinda Nayyar, Vandana Suri, Poonam Khokhar, Brinda Nayyar, Poonam Khokhar, Jon E Rohde, Tivendra Kumar, Jose Martines, Maharaj K Bhan, and all other members of the study staffs and field teams. We would also like to thank all study participants and their families for their important contributions.

Author contributions

Conceptualization: J.B., A.M., J.M.C., K.H.B., P.C., B.F.A

Funding Acquisition: J.M.C., A.E.H., M.J.V., B.F.A.

Data curation: J.B., A.M., J.C., O.S., W.C., A.N., N.N.P., W.J., E.O.C., S.D., N.H., I.M., H.L., R.H., V.S., J.H., T.N.

Formal analyses: J.B., A.M., J.C., O.S., W.C., A.N., N.N.P., W.J., E.O.C., S.D., N.H., I.M., H.L., V.S., B.F.A

Methodology: J.B., A.M., J.M.C, J.C., O.S., N.H., I.M., A.E.H., M.J.V.,K.H.B., P.C., B.F.A.

Visualization: J.B., A.M., A.N., N.N.P., S.D., A.S., J.C., R.H., K.H.B., P.C., B.F.A.

Writing – Original Draft Preparation: J.B., A.M., B.F.A.

Writing – Review & Editing: J.B., A.M., J.M.C., K.H.B., P.C., B.F.A., *ki* Child Growth Consortium members

Competing interest declaration

Thea Norman is an employee of the Bill & Melinda Gates Foundation (BMGF). Kenneth H Brown and Parul Christian are former employees of BMGF. Jeremy Coyle, Vishak Subramoney, Ryan Hafen, and Jonas Häggström work as research contractors funded by the BMGF.

Additional information

Supplementary Information is available for this paper here: https://child-growth.github.io/stunting/

Correspondence and requests for materials should be addressed to Jade Benjamin-Chung (jadebc@berkeley.edu) and Benjamin F. Arnold (ben.arnold@ucsf.edu).

Extended Data Figure 1| *ki* cohort selection. Analyses focused on longitudinal cohorts to enable the estimation of prospective incidence rates and growth velocity. In April 2018, there were 86 longitudinal studies on GHAP. From this set, we applied five inclusion criteria to select cohorts for analysis. Our rationale for each criterion follows. (1) *Studies were conducted in lower income or middle-income countries*. Our target of inference for analyses was children in LMICs, which remains a key target population for preventive interventions. (2) *Studies measured length and weight between birth and age 24 months*. We were principally interested in growth faltering during the first 1,000 days (including gestation), thought to be the key window for linear growth faltering.[7] (3) *Studies did not restrict enrollment to acutely ill children*. Our focus on descriptive analyses led us to target, to the extent possible, the general population. We thus excluded some studies that exclusively enrolled acutely ill children, such as children who presented to hospital with acute diarrhea or who were severely malnourished. (4) *Studies enrolled at least 200 children*. Age-stratified incident episodes of stunting and wasting were sufficiently rare that we wanted to ensure each cohort would have enough information to estimate rates before contributing to pooled estimates. (5) *Studies collected anthropometry measurements at least every 3 months*. We limited studies to those with higher temporal resolution to ensure that we adequately captured incident episodes and recovery.

Extended Data Figure 2 | Stunting prevalence by geographic location of *ki* cohorts. Locations are approximate, represented as nation-level centroids and jittered slightly for display. The size of each centroid indicates the number of observations contributing to each estimate. The color of each centroid indicates the level of stunting prevalence.

886
887 **Extended Data Figure 3 | Mean, 5th and 95ᵗʰ percentile of length-for-age Z-score** by age in *ki*
888 longitudinal cohorts estimated with cubic splines in cohorts with at least monthly measurement (N=14
889 cohorts that measured children at least monthly, N=7,456 children).
890

Extended Data Figure 4 | Linear growth velocity by age and sex stratified by region. a) Within-child difference in length in centimeters per month stratified by age, sex, and region. Dotted black line indicates 15th percentile of the WHO Growth Velocity Standards; dashed black line indicates the 25th percentile; solid black line indicates the 50th percentile. Colored lines indicate and vertical bars indicate 95% confidence intervals for *ki* cohorts. (**b**) Within-child difference in length-for-age Z-score per month by age, sex, and region. (**c**) Mean length-for-age Z-score by age, sex, and region. Results shown in all panels were derived from 29 *ki* cohorts in 13 countries that measured children at least quarterly (n = 50,022 children).

Extended Data Figure 5 | Comparison of stunting prevalence at birth with and without gestational age correction

This figure includes the results from correcting at-birth Z-scores in the *ki* cohorts that measured gestational age (GA) for 37,218 measurements in 8 cohorts. The number in the parentheses following each cohort name indicates the prevalence of pre-term birth in each cohort. The corrections are using the Intergrowth standards and are implemented using the R *growthstandards* package (https://ki-tools.github.io/growthstandards/). Overall, the stunting prevalence at birth decreased slightly after correcting for gestational age, but the cohort-specific results are inconsistent. Observations with GA outside of the Intergrowth standards range (<168 or > 300 days) were dropped for both the corrected and uncorrected data. Prevalence increased after GA correction in some cohorts due to high rates of late-term births based on reported GA. Gestational age was estimated based on mother's recall of the last menstrual period in the Jivita-3, Cebu, New Delhi, INCAP, IRC, and CMC-V-BCS-2002 cohorts, was based on the Dubowitz method (newborn exam) in the Keneba cohort, and was based on ultrasound measurements in the PROBIT trial.

Extended Data Table 1| Summary of *ki* cohorts

Region, Study ID	Country	Study Years	Design	Children Enrolled*	Anthropo-metry measure-ment ages (months)	Total measure-ments*	Primary References
South Asia							
Biomarkers for EE	Pakistan	2013-2015	Prospective cohort	379	Birth, 1, 2, ..., 18	8484	Iqbal et al 2018 Nature Scientific Reports[1]
Resp. Pathogens	Pakistan	2011 - 2014	Prospective cohort	284	Birth, 1, 2, ..., 17	3177	Ali et al 2016 Journal of Medical Virology[2]
Growth Monitoring Study	Nepal	2012 - Ongoing	Prospective cohort	698	Birth, 1, 2, ..., 24	13465	Not yet published
MAL-ED	Nepal	2010 - 2014	Prospective cohort	240	Birth, 1, 2, ..., 24	5703	Shrestha et al 2014 Clin Infect Dis[3]
CMC Birth Cohort, Vellore	India	2002 - 2006	Prospective cohort	373	Birth, 0.5, 1, 1.5, ..., 24	8709	Gladstone et al. 2011 NEJM[4]
MAL-ED	India	2010 - 2012	Prospective cohort	251	Birth, 1, 2, ..., 24	5702	John et al 2014 Clin Infect Dis[5]
Vellore Crypto Study	India	2008 - 2011	Prospective cohort	410	Birth, 1, 2, ..., 24	9771	Kattula et al. 2014 BMJ Open[6]
CMIN	Bangladesh	1993 - 1996	Prospective Cohort	277	Birth, 3, 6, ..., 24	5363	Pathela et al 2007 Acta Paediatrica[7]
MAL-ED	Bangladesh	2010 - 2014	Prospective cohort	265	Birth, 1, 2, ..., 24	5604	Ahmed et al 2014 Clin Infect Dis[8]
PROVIDE RCT	Bangladesh	2011 - 2014	Individual RCT	700	Birth, 6, 10, 12, 14. 17, 18, 24, 39, 40, 52, 53 (weeks)	9207	Kirkpatrick et al 2015 Am J Trop Med Hyg[9]
Food Suppl RCT	India	1995 - 1996	Individual RCT	418	Baseline, 6, 9, 12	2232	Bhandari et al 2001 J Nutri[10]
Optimal Infant Feeding	India	1999 - 2001	Cluster RCT	472	Birth, 3, 6, ..., 18	2948	Bhandari et al 2004 J Nutri[11]
New Delhi Birth Cohort	India	1969 - 2002	Prospective cohort	7417	Birth, 3, 6, 9, 12, 18, 24	31844	Bhargava et al 2009 NEJM[12]
NIH Birth Cohort	Bangladesh	2008 - 2009	Prospective Cohort	629	Birth, 3, 6, ..., 12	6215	Korpe et al. 2016 PLOS NTD[13]

Study	Country	Years	Study type	N	Ages	N obs	Reference
JiVitA-4 Trial	Bangladesh	2012 - 2014	Cluster RCT	1434	6, 9, 12, 14, 18	9344	Christian et al 2015 IJE[14]
JiVitA-3 Trial	Bangladesh	2008 - 2012	Cluster RCT	13475	Birth, 1, 3, 6, 12, 24	53453	West et al JAMA 2014[15]
NIH Cryptosporidium Study	Bangladesh	2014 - 2017	Prospective cohort	758	Birth, 3, 6, ..., 24	6914	Steiner et al 2018 Clin Infect Dis[16]
The Cebu Longitudinal Health and Nutrition Survey	Philippines	1983 - 2005	Prospective cohort	3058	Birth, 2, 4, ..., 24	32518	Adair 2007 Am J Hum Biol[17]
Africa							
MAL-ED	Tanzania	2009 - 2014	Prospective cohort	262	Birth, 1, 2, ..., 24	5713	Mduma et al 2014 Clin Infect Dis[18]
Tanzania Child 2	Tanzania	2007 - 2011	Individual RCT	2396	1, 2, ..., 20	29565	Locks et al Am J Clin Nutr 2016[19]
MAL-ED	South Africa	2009 - 2014	Prospective cohort	314	Birth, 1, 2, ..., 24	6163	Bessong et al 2014 Clin Infect Dis[20]
MRC Keneba	Gambia	1987 - 1997	Cohort	2915	Birth, 1, 2, ..., 24	40275	Schoenbuchner et al. 2019, AJCN[21]
ZVITAMBO Trial	Zimbabwe	1997 - 2001	Individual RCT	14074	Birth, 6 wks, 3, 6, 9, 12	71928	Malaba et al 2005 Am J Clin Nutr[22]
Lungwena Child Nutrition RCT	Malawi	2011 - 2014	Individual RCT	840	Birth, 1-6 wk, 6, 12 18	4336	Mangani et al. 2015, Mat Child Nutr[23]
iLiNS-Zinc Study	Burkina Faso	2010 - 2012	Cluster RCT	797	9, 12, 15, 18	1471	Hess et al 2015 Plos One[24]
Latin America							
MAL-ED	Peru	2009 - 2014	Prospective cohort	303	Birth, 1, 2, ..., 24	6142	Yori et al 2014 Clin Infect Dis[25]
CONTENT	Peru	2007 - 2011	Prospective cohort	215	Birth, 1, 2, ..., 24	8339	Jaganath et al 2014 Helicobacter[26]
Bovine Serum RCT	Guatemala	1997 - 1998	Individual RCT	315	Baseline, 1, 2, ...,8	2545	Begin et al. 2008, EJCN[27]
MAL-ED	Brazil	2010 - 2014	Prospective cohort	233	Birth, 1, 2, ..., 24	4858	Lima et al 2014 Clin Infect Dis[28]
INCAP Nutrition Supplementation Trial Longitudinal Study	Guatemala	1969 - 1977	Cluster RCT	664	Birth, 3, 6, ..., 24	3708	Habicht et al 1995 J Nutr[29]

Europe							
PROBIT Study	Belarus	1996 - 1997	Cluster RCT	8127	1, 2, 3, 6, 9, 12	58649	Kramer et al 2001 JAMA[30]
*Children enrolled is for children with measurements under 2 years of age. Total measurements are number of measurements of anthropometry on children under 2 years of age.							

921
922

Extended Data Table 2| Countries and survey years included in the analysis of Demographic and Health Survey data

Africa	
Burkina Faso	2010
Gambia	2013
Malawi	2015-2016
Tanzania	2015-2016
South Africa	2016
Zimbabwe	2015
South Asia	
Bangladesh	2014
India	2015-2016
Nepal	2016
Pakistan	2017-2018
Latin America	
Guatemala	2014-2015
Peru	2012

Extended Data References

1. Iqbal, N. T. *et al.* Promising Biomarkers of Environmental Enteric Dysfunction: A Prospective Cohort study in Pakistani Children. *Sci. Rep.* **8**, 2966 (2018).
2. Ali, A. *et al.* Respiratory viruses associated with severe pneumonia in children under 2 years old in a rural community in Pakistan. *J. Med. Virol.* **88**, 1882–1890 (2016).
3. Shrestha, P. S. *et al.* Bhaktapur, Nepal: The MAL-ED Birth Cohort Study in Nepal. *Clin. Infect. Dis.* **59**, S300–S303 (2014).
4. Gladstone, B. P. *et al.* Protective Effect of Natural Rotavirus Infection in an Indian Birth Cohort. *N. Engl. J. Med.* **365**, 337–346 (2011).
5. John, S. M. *et al.* Establishment of the MAL-ED Birth Cohort Study Site in Vellore, Southern India. *Clin. Infect. Dis.* **59**, S295–S299 (2014).
6. Kattula, D. *et al.* The first 1000 days of life: prenatal and postnatal risk factors for morbidity and growth in a birth cohort in southern India. *BMJ Open* **4**, e005404 (2014).
7. Pathela, P. *et al.* Diarrheal illness in a cohort of children 0-2 years of age in rural Bangladesh: I. Incidence and risk factors: Risk factors for diarrhea in Bangladeshi children. *Acta Paediatr.* **95**, 430–437 (2007).
8. Ahmed, T. *et al.* The MAL-ED Cohort Study in Mirpur, Bangladesh. *Clin. Infect. Dis.* **59**, S280–S286 (2014).
9. Kirkpatrick, B. D. *et al.* The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) Study: Description of Methods of an Interventional Study Designed to Explore Complex Biologic Problems. *Am. J. Trop. Med. Hyg.* **92**, 744–751 (2015).
10. Bhandari, N. *et al.* Food Supplementation with Encouragement to Feed It to Infants from 4 to 12 Months of Age Has a Small Impact on Weight Gain. *J. Nutr.* **131**, 1946–1951 (2001).

11. Bhandari, N. *et al.* An Educational Intervention to Promote Appropriate Complementary Feeding Practices and Physical Growth in Infants and Young Children in Rural Haryana, India. *J. Nutr.* **134**, 2342–2348 (2004).

12. Bhargava, S. K. *et al.* Relation of Serial Changes in Childhood Body-Mass Index to Impaired Glucose Tolerance in Young Adulthood. *N. Engl. J. Med.* **350**, 865 (2004).

13. Korpe, P. S. *et al.* Natural History of Cryptosporidiosis in a Longitudinal Study of Slum-Dwelling Bangladeshi Children: Association with Severe Malnutrition. *PLoS Negl. Trop. Dis.* **10**, (2016).

14. Christian, P. *et al.* Effect of fortified complementary food supplementation on child growth in rural Bangladesh: a cluster-randomized trial. *Int. J. Epidemiol.* **44**, 1862–1876 (2015).

15. West, K. P. *et al.* Effect of Maternal Multiple Micronutrient vs Iron–Folic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial. *JAMA* **312**, 2649–2658 (2014).

16. Steiner, K. L. *et al.* Species of Cryptosporidia Causing Subclinical Infection Associated With Growth Faltering in Rural and Urban Bangladesh: A Birth Cohort Study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **67**, 1347–1355 (2018).

17. Adair, L. S. Size at birth and growth trajectories to young adulthood. *Am. J. Hum. Biol. Off. J. Hum. Biol. Counc.* **19**, 327–337 (2007).

18. Mduma, E. R. *et al.* The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development Study (MAL-ED): Description of the Tanzanian Site. *Clin. Infect. Dis.* **59**, S325–S330 (2014).

19. Locks, L. M. *et al.* Effect of zinc and multivitamin supplementation on the growth of Tanzanian children aged 6–84 wk: a randomized, placebo-controlled, double-blind trial12. *Am. J. Clin. Nutr.* **103**, 910–918 (2016).

20. Bessong, P. O., Nyathi, E., Mahopo, T. C. & Netshandama, V. Development of the Dzimauli Community in Vhembe District, Limpopo Province of South Africa, for the MAL-ED Cohort Study. *Clin. Infect. Dis.* **59**, S317–S324 (2014).

21. Schoenbuchner, S. M. *et al.* The relationship between wasting and stunting: a retrospective cohort analysis of longitudinal data in Gambian children from 1976 to 2016. *Am. J. Clin. Nutr.* doi:10.1093/ajcn/nqy326.

22. Malaba, L. C. *et al.* Effect of postpartum maternal or neonatal vitamin A supplementation on infant mortality among infants born to HIV-negative mothers in Zimbabwe. *Am. J. Clin. Nutr.* **81**, 454–460 (2005).

23. Mangani, C. *et al.* Effect of complementary feeding with lipid-based nutrient supplements and corn–soy blend on the incidence of stunting and linear growth among 6- to 18-month-old infants and children in rural Malawi. *Matern. Child. Nutr.* **11**, 132–143 (2015).

24. Hess, S. Y. *et al.* Small-Quantity Lipid-Based Nutrient Supplements, Regardless of Their Zinc Content, Increase Growth and Reduce the Prevalence of Stunting and Wasting in Young Burkinabe Children: A Cluster-Randomized Trial. *PLOS ONE* **10**, e0122242 (2015).

25. Yori, P. P. *et al.* Santa Clara de Nanay: The MAL-ED Cohort in Peru. *Clin. Infect. Dis.* **59**, S310–S316 (2014).

26. Jaganath, D. *et al.* First Detected Helicobacter pylori Infection in Infancy Modifies the Association Between Diarrheal Disease and Childhood Growth in Peru. *Helicobacter* **19**, 272–279 (2014).

27. Bégin, F., Santizo, M.-C., Peerson, J. M., Torún, B. & Brown, K. H. Effects of bovine serum concentrate, with or without supplemental micronutrients, on the growth, morbidity, and micronutrient status of young children in a low-income, peri-urban Guatemalan community. *Eur. J. Clin. Nutr.* **62**, 39–50 (2008).

28. Lima, A. A. M. *et al.* Geography, Population, Demography, Socioeconomic, Anthropometry, and Environmental Status in the MAL-ED Cohort and Case-Control Study Sites in Fortaleza, Ceará, Brazil. *Clin. Infect. Dis.* **59**, S287–S294 (2014).

1005   29. Habicht, J.-P., Martorell, R. & Rivera, J. A. Nutritional Impact of Supplementation in the
1006   INCAP Longitudinal Study: Analytic Strategies and Inferences. *J. Nutr.* **125**, 1042S-1050S
1007   (1995).
1008   30. Kramer, M. S. *et al.* Promotion of Breastfeeding Intervention Trial (PROBIT): A Randomized
1009   Trial in the Republic of Belarus. *JAMA* **285**, 413–420 (2001).
1010